Beerse | Jotup

DGAP-News: Aurubis AG: ASPA: Aurubis introduces more efficient way of recycling

Retrieved on:

Wednesday, July 28, 2021

Aurubis, Copper, Water conservation, Recycling, Beerse, Industry economics), Secondary sector of the economy, Nature

Hamburg/Beerse, July 28, 2021 - Today, Aurubis announced the construction of a state-of-the-art recycling facility at its Beerse site in Belgium.

Key Points:

Hamburg/Beerse, July 28, 2021 - Today, Aurubis announced the construction of a state-of-the-art recycling facility at its Beerse site in Belgium.
With ASPA, our production in Beerse is becoming faster, more efficient, and with less valuable metal loss," Dr. Heiko Arnold, COO of Aurubis AG, said.
ASPA uses the in-house recycling know-how of the Beerse plant and grafts it into the processes of other Aurubis plants."
Valorizing metals from this end-of-life pool in a sustainable way therefore requires special recycling skills and investment in research and development.

Surface Oncology Appoints Denice Torres to Board of Directors

Retrieved on:

Thursday, July 8, 2021

Health care, Life sciences, Johnson & Johnson, Companies, Beerse, Janssen Pharmaceuticals, Medical research, Cancer immunotherapy

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Denice Torres will join the companys board of directors.

Key Points:

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Denice Torres will join the companys board of directors.
I am thrilled to welcome Denice to the Surface board.
At Johnson & Johnson, Ms. Torres held several executive leadership positions, including president of McNeil Consumer Healthcare and president of Janssen Pharmaceuticals, CNS.
In addition, any forward-looking statements contained in this press release are based on assumptions that Surface Oncology believes to be reasonable as of this date.

Cidara Therapeutics Provides Leadership Update

Retrieved on:

Thursday, July 1, 2021

Beerse, Janssen Pharmaceuticals, Johnson & Johnson, Medical research, Pharmaceutical industry in China, Health

Mr. Levine will continue to serve as a consultant to the Company for at least six months and will provide transitional support to a successor CFO.

Key Points:

Mr. Levine will continue to serve as a consultant to the Company for at least six months and will provide transitional support to a successor CFO.
On behalf of the entire Cidara team and board of directors, I want to thank Jamie for his financial leadership, including his significant contributions to our collaborations with Mundipharma and Janssen Pharmaceuticals, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.
Cidara is headquartered in San Diego, California.

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on:

Tuesday, June 1, 2021

Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health care, Medicine, Health sciences, Beerse, Janssen Pharmaceuticals, Johnson & Johnson, Medical research, Multiple myeloma, Chimeric antigen receptor T cell, GenScript Biotech, Bluebird bio

Janssen Pharmaceutical NV, Janssen Research & Development, LLC, and Janssen-Cilag Limited are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Key Points:

Janssen Pharmaceutical NV, Janssen Research & Development, LLC, and Janssen-Cilag Limited are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma.
Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma.
Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma.

Johnson & Johnson's Scott White Elected To CEO Roundtable On Cancer Board Of Directors

Retrieved on:

Monday, May 24, 2021

Life sciences, Beerse, Janssen Pharmaceuticals, Johnson & Johnson, Medical research, Health care, Companies

CARY, N.C., May 24, 2021 /PRNewswire/ --The CEO Roundtable on Cancer has elected Scott White, Company Group Chairman for North America at the Janssen Pharmaceutical Companies of Johnson & Johnson, to its Board of Directors.

Key Points:

CARY, N.C., May 24, 2021 /PRNewswire/ --The CEO Roundtable on Cancer has elected Scott White, Company Group Chairman for North America at the Janssen Pharmaceutical Companies of Johnson & Johnson, to its Board of Directors.
Bush founded the non-profit CEO Roundtable on Cancer in 2001 to bring bold and imaginative solutions to cancer treatment and prevention.
"We are grateful that he will be joining the Board and continuing a tradition of close collaboration from Johnson & Johnson."
"Special recognition and thanks go to Joaquin Duato for five years of service to the CEO Roundtable Board," Mr. Lee said.

Janssen Receives Positive CHMP Opinion for PONVORY™ ▼ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features

Retrieved on:

Friday, March 26, 2021

Biotechnology, Health, Pharmaceutical, Managed care, Oncology, Multiple sclerosis, Immunosuppressants, Medical specialties, Johnson & Johnson, Health care, Medicine, Beerse, Janssen Pharmaceuticals, Medical research, Janssen, Ponesimod, Ponesimod, Multiple Sclerosis, the Janssen Pharmaceutical Companies of Johnson & Johnson

If approved by the European Commission, ponesimod has the potential to help more people living with relapsing forms of MS.

Key Points:

If approved by the European Commission, ponesimod has the potential to help more people living with relapsing forms of MS.
If approved, ponesimod will be the first therapy by Janssen for patients living with RMS with active disease defined by clinical or imaging features.
Janssen Research & Development, LLC and Janssen Pharmaceutica NV are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Janssen Submits European Marketing Authorisation Application for Ponesimod for Treatment of Adults with Relapsing Multiple Sclerosis.

Verana Health Announces Real-World Data and Data Science Collaboration Agreement with Janssen

Retrieved on:

Wednesday, January 27, 2021

Verana Health , a leader in transforming clinical data into actionable real-world evidence, today announced a research collaboration agreement with Janssen Research & Development, LLC (Janssen).

Key Points:

Verana Health , a leader in transforming clinical data into actionable real-world evidence, today announced a research collaboration agreement with Janssen Research & Development, LLC (Janssen).
The research collaboration will focus on curating real-world data and driving data science applications in the areas of ophthalmology and urology.
Through the agreement, Verana Health aims to further advance the utilization of real-world evidence and data science to inform research and development.
These partnerships enable Verana Health to harness the comprehensive data found in qualified clinical data registries and other specialty data sources to accelerate medical research and enhance patient care.

DGAP-News: BioMed X GmbH: BioMed X Institute announces expansion of their strategic collaboration with Janssen in immunology research

Retrieved on:

Monday, November 9, 2020

Johnson & Johnson, Beerse, Janssen Pharmaceutica, Medical research, Companies, Health sciences, BIOMED, BioMed Central, Health care

German independent research institute BioMed X adds a further research program in the field of immunology to their existing collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson: The new project will focus on the development of novel methodologies to systematically profile and dissect complex tissue microenvironments.

Key Points:

German independent research institute BioMed X adds a further research program in the field of immunology to their existing collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson: The new project will focus on the development of novel methodologies to systematically profile and dissect complex tissue microenvironments.
Christian Tidona, Founder and Managing Director of BioMed X Institute: "We are excited to expand our collaboration with Janssen with a second research project in the field of autoimmune diseases.
BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany.
Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry.

Tempus Announces Strategic Collaboration With Janssen Applying Data Science to Enhance Therapeutic Development

Retrieved on:

Monday, November 2, 2020

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a strategic collaboration with Janssen Research & Development, LLC (Janssen), in which Tempus will work closely with Janssen data scientists and oncologists focused on oncology clinical development programs.

Key Points:

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a strategic collaboration with Janssen Research & Development, LLC (Janssen), in which Tempus will work closely with Janssen data scientists and oncologists focused on oncology clinical development programs.
The collaboration will leverage the full capabilities of Tempus with those of Janssen with the intent of bringing the power of precision medicine to address the needs of cancer patients.
As part of the collaboration, Tempus is developing a predictive model using machine learning techniques to enhance enrollment in Janssens biomarker-driven clinical trials.
In addition, Janssen has joined The TIME Trial Network, Tempus clinical trial program which brings clinical trials to communities across the country, offering patients access to novel therapies under development.

Enigma Biomedical Group Signs Agreement to License Novel Neuro Imaging Biomarkers From Janssen

Retrieved on:

Monday, August 31, 2020

Enigma Biomedical Group (EBG) today announced execution of a Master Development, License and Option Agreement and two Project Agreements to evaluate novel neuroimaging biomarkers from Janssen Pharmaceutica N.V. (Janssen), part of The Janssen Pharmaceutical Companies of Johnson & Johnson.

Key Points:

Enigma Biomedical Group (EBG) today announced execution of a Master Development, License and Option Agreement and two Project Agreements to evaluate novel neuroimaging biomarkers from Janssen Pharmaceutica N.V. (Janssen), part of The Janssen Pharmaceutical Companies of Johnson & Johnson.
If the evaluations are successful and EBG exercises its option, then EBG and Janssen will negotiate to enter into an exclusive license agreement.
Toronto-based Enigma Biomedical Group (EBG) enhances access to key technologies with a focus on molecular imaging and medicine.
Cerveau Technologies, Inc. is a collaboration between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group.